SCHEMBL967296

SCHEMBL967296

CCN(C(=O)O)[C@@H]1CCCNC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 10/20 0.47
SLC6A4 P31645 10/20 0.47
SLC6A3 Q01959 7/20 0.47
SLC6A1 P30531 2/20 0.44
SLC6A11 P48066 1/20 0.44
TSHR P16473 1/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SLC6A13 Q9NSD5 1/20 0.44
KCNH2 Q12809 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.41
REN P00797 1/20 0.39
CPN1 P15169 1/20 0.39
CPB2 Q96IY4 1/20 0.39
CYP2D6 P10635 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14632098 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11
SCHEMBL1468566 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11
SCHEMBL968086 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11
SCHEMBL15667928 0.89 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL1840824 0.89 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL16104131 0.88 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11
SCHEMBL966683 0.86 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11
SCHEMBL2875169 0.83 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11
SCHEMBL17786300 0.83 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11
SCHEMBL967276 0.82 L3MBTL1 (0.49) SLC6A2SLC6A4LMNAL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 US claimed
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 US disclosed
EP-2269986-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR Sumitomo Chemical Company, Limited (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR PDCD2L, NOTUM, OXA1L SLC6A2 4872/4885SLC6A4 4186/4885SLC6A3 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.